Symbiotec Pharmalab Secures ₹526 Crore Anchor Book Ahead of Massive ₹1,757-Crore IPO Launch
Madhya Pradesh's contract development and manufacturing organization (CDMO), Symbiotec Pharmalab, successfully raised a substantial amount through its anchor book. The company secured Rs 526.2 crore from 34 key anchor investors, setting a strong tone just one day before the launch of its Initial Public Offering (IPO).The IPO is scheduled to open for public subscription on August 24 and close by August 27. With the price band set at Rs 938-988 per share, this offering represents a significant opportunity in the specialty pharmaceutical market.
Investor Confidence Booms as Anchors Flock to Symbiotec Pharmalab
The allocation of 53.25 lakh equity shares to the anchor investors at Rs 988 per share underscores strong institutional confidence. Key institutions that committed included Citigroup Global Markets, BNP Paribas, Singularity AMC (backed by Madhusudan Kela), Susquehanna Pacific, and TIMF Holdings.A significant portion of the subscription came from domestic mutual funds. Eleven Indian mutual funds, including ICICI Prudential AMC and HDFC Mutual Fund, picked up 31.98 lakh shares through 19 different schemes.
IPO Structure and Proceeds Utilization Explained
The Symbiotec Pharmalab IPO is structured with a fresh issue of shares valued at Rs 150 crore. This complements the large Offer for Sale (OFS) amounting to Rs 1,607 crore. The OFS involves selling shareholders including Promoter Satwani Holdings, Rosewood Investments, and Motilal Oswal.The proceeds from the IPO are earmarked for strategic corporate use. Symbiotec Pharmalab plans to utilize Rs 112.5 crore from the net fresh issue proceeds specifically for debt repayment. The remainder of the fresh issue capital will be designated for general corporate purposes.
Manufacturing Capacity and Business Model Overview
Symbiotec Pharmalab operates as a crucial CDMO, providing manufacturing services to specialty pharmaceutical and nutraceutical companies worldwide. Its core operations are built around three specialized platforms: organic chemistry, biotechnology, and complex injectables.The company possesses two operational industrial-scale active pharmaceutical ingredient (API) manufacturing facilities. These plants boast a maximum chemical synthesis capacity of 584.67 metric tonnes (MT) and a fermentation capacity of 300 kilolitres (KL).
Strategic Expansion in Biotechnology Operations
Further bolstering its future growth, Symbiotec Pharmalab has commissioned two additional manufacturing facilities at Ujjain and Mhow within Madhya Pradesh. The company is actively expanding its biologics capability.A planned addition includes a dedicated 14 KL fermentation facility for biologics manufacturing, which will be established at the Ujjain site to enhance specialized services.
Financial Performance Highlights Over Recent Years
The company has shown consistent growth in both revenue and profitability. Symbiotec Pharmalab’s revenue has increased at a Compound Annual Growth Rate (CAGR) of 10.16 percent, reaching Rs 869.1 crore in FY26. The firm's profit also displayed steady growth, increasing at a CAGR of 4.81 percent to reach Rs 109.9 crore in FY26 from FY24.The IPO process is being managed by JM Financial, Avendus Capital, Motilal Oswal Investment Advisors, and Nomura Financial Advisory and Securities (India) as the book-running lead managers.
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.